April 2023 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Your Moves
Movers of the Month
Dr Steve Lloyd joins Conclusio in the role of Clinical Director. This will further strengthen its core team and panel of NHS subject matter experts.
Steve has a rich clinical background. Following an initial career stage as a maxillofacial surgeon, he entered general practice spending over 20 years as a GP in Derbyshire. Concurrent with this, he was Chair of NHS Hardwick CCG from inception in 2012 until 2018 with the merger of the four Derbyshire CCGs to form NHS Derby and Derbyshire CCG.
At this point, he accepted the role of Executive Medical Director for NHS Derby and Derbyshire Clinical Commissioning Group – now Derbyshire ICB. Here he led and had budget responsibility for primary care co-commissioning and quality, medicines management and clinical policy, GP IT infrastructure and developing a bespoke clinical leadership structure alongside strategic long-term conditions commissioning.
He also has increased his experience in other clinical lead roles, including substance misuse, and urgent and emergency care provision. Steve was also the executive SRO for the award-winning COVID-19 vaccination and community treatment programmes across Derbyshire.
Inizio has strengthened its senior leadership team with the appointment of Stefanie Christmas as its new Global Head of Diversity, Equity & Inclusion (DE&I).
In her new role, Stefanie will be responsible for developing an organisation-wide DE&I strategy, working with individual business unit leaders to deliver operational alignment and accountability.
Stefanie is a highly experienced professional with a breadth of expertise in strategic planning and organisational effectiveness, spanning the public and private sectors and multiple industries.
She joins the Inizio executive team from Vynamic, where she made her mark by founding its DE&I efforts in 2016, developing a vision and mission to align with its values and culture.
ACG has announced that Richard Stedman will be rejoining the business as the Group CEO of the engineering division. Richard is a seasoned executive in the engineering industry and has previously held the position of CEO at ACG Engineering from 2017 to 2021.
His previous tenure as CEO was marked by significant growth and achievement. During his time at ACG, he oversaw the successful completion of several high-profile projects, and was instrumental in expanding the company's presence in key global markets.
With over 35 years’ experience working in the packaging, engineering and pharmaceutical manufacturing industries Richard has led and transformed multiple businesses across South Africa, Singapore, New Zealand, Australia and India, bringing extensive expertise across multidisciplinary functions.
VectorY Therapeutics, a biotech company developing disease-modifying vectorised antibody therapies for the treatment of neurodegenerative diseases, has announced the appointment of Michael Wyzga as Chief Financial Officer (CFO) and Jean Franchi as Independent Board member and Chair of the Audit Committee.
Michael most recently served as the CFO of Yumanity Therapeutics, where he managed the sale of assets to Janssen Phamaceutica and a merger with Kineta. Prior to Yumanity Therapeutics, Michael spent over a decade in several investment banking roles, including Needham & Company and Citigroup.
Jean has over 30 years of experience in biotech operations, from pre-commercial to global commercial companies. She is currently CFO at Replimune, a company developing tumour-directed oncolytic immunotherapies. Jean previously served in the same role at Merrimack Pharmaceuticals, Dimension Therapeutics and Good Start Genetics, and was also Senior Vice President of Corporate Finance at Genzyme.
Azafaros B.V. has announced two appointments to its executive management team. Silvia Ragno joins the company as Chief Operating Officer and Henrik Torp Nielsen as Head of Finance.
Silvia worked in the global pharmaceutical industry for 20 years before joining Azafaros. She co-founded Stargazer Pharmaceuticals and acted as Chief Operating Officer for the company leading the preclinical and clinical programme strategy for the development of a new treatment for the rare genetic Stargardt’s disease.
With more than 15 years of experience in the international pharmaceutical industry, Henrik brings a particularly diversified knowledge of business development, innovation and medical market access to Azafaros. He previously held several senior roles at Novartis, notably European Head of Business Development Finance, Oncology.
CN Bio has announced the appointment of Deepak Singh as Vice President of Sales and Marketing. Deepak’s appointment supports the Company’s next phase of commercial development as it expands international operations, product research and development and sales in key global markets.
Throughout his extensive 30-year career in the commercial life sciences sector, Deepak has provided leadership for high-performance sales and marketing teams to establish new technologies, from commercialisation through to global scale-up, as well as supporting expansion of existing products and services into the drug discovery, bioproduction, research and diagnostics markets.
He joins CN Bio from PerkinElmer’s Horizon Discovery where he was Head of Global Commercial. Prior to this, Deepak was with Pacific Biosciences as Vice President of EMEA Operations.
Koa Health has announced that Dr Anna Mandeville has joined the company’s team as UK Clinical Director, while Leslie Norwalk has been appointed to the company’s Supervisory Board. Anna will oversee the development of Koa Health’s clinical services, and Leslie will serve as an advisor on the US healthcare system.
Anna brings a wealth of experience in Clinical Psychology to the Koa Health Team. She most recently served as Divisional Lead for Psychological Services in Enfield at BEH Mental Health Trust in the UK, where she led the service design and quality monitoring of a range of physical and mental health services.
Leslie’s extensive leadership experience in the US Government healthcare industry brings an invaluable perspective to Koa Health. Previously, Leslie served as acting administrator for the Centers for Medicare & Medicaid Services. Throughout her career, she has also served on boards across a wide spectrum of healthcare corporations and biotechnology companies.
VarmX, a company focusing on the reversal of anticoagulation, has announced the appointment of Dr Jeffrey Lawson as its new Chief Scientific Officer.
Jeffrey is a renowned scientist in blood coagulation biochemistry and surgical haemostasis, and also a clinical vascular surgeon who brings over 20 years of experience in the development of haemostatic products and vascular technologies. Prior to joining VarmX, he served as the President and Chief Executive Officer of Humacyte, a NASDAQ-listed regenerative medicine company, where he oversaw the clinical development of the company's vascular technologies. He also co-founded InnAVasc, a vascular device company dedicated to safe and reliable vascular access for haemodialysis, which was recently acquired by Gore.
Myeloma UK is delighted to announce the appointment of Professor Graham Jackson as its first Chief Clinical and Scientific Advisor.
Graham has been a consultant haematologist at the Freeman Hospital in Newcastle for nearly 30 years and has dedicated his career to supporting patients with myeloma, AL amyloidosis and related conditions.
The new role will enable Myeloma UK to embed a unique perspective into its clinical and scientific thought leadership to ensure that the charity remains at the cutting edge of insight and innovation for myeloma patients.
Working with the Chief Executive and leadership team, the Chief Clinical and Scientific Advisor will provide insight to help inform the charity’s research strategy and guide the development of its patient information and support services.
The ABPI Board has confirmed that Susan Rienow – UK Country President of Pfizer – will be the next President of the Association of the British Pharmaceutical Industry (ABPI).
Susan was appointed as ABPI Vice-President in September 2022 and will formally take up her role as President in May 2023. As President, Susan will lead the ABPI Board to deliver the organisation's mission to make the UK the best place in the world to research, develop and use new medicines and vaccines.
At Pfizer, Susan leads the organisation across the breadth of Pfizer’s innovative medicines and vaccines portfolio. She previously led Pfizer UK’s Vaccines business unit during the COVID-19 pandemic.
Janneke van der Kamp has assumed her role as the new Chief Commercial Officer of Grünenthal. She joins Grünenthal’s executive board and is responsible for the entire Global Commercial Organisation.
As CCO of Grünenthal, Janneke’s focus will be to further strengthen Grünenthal’s commercial activities and grow the company’s key brands, especially Qutenza.
Janneke joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles, including General Manager, Global Neurosciences Franchise Head and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio.
uMotif – a clinical trial technology company – has announced that life sciences and healthcare executive Adam Deutsch has joined its Board of Directors.
The company’s platform combines deep clinical knowledge and consumer design expertise to deliver unprecedented levels of patient compliance, regularly achieving greater than 90% data capture in real-world studies.
Adam has earned a reputation across life sciences and healthcare for his solid track record of helping companies uphold transformational business opportunities while navigating regulatory complexity.
Osivax, a company focused on preventing the spread of constantly mutating global infectious diseases, has announced the appointment of Dr Chris Martin to its Board of Directors.
Chris brings over 20 years of biotech and pharmaceutical experience, and has successfully brought several candidates from clinical evaluation through marketing approval. He is a co-founder and board member of ADC Therapeutics, a commercial-stage biotechnology company specialised in Antibody-Drug-Conjugates.
He was also the co-founder of Spirogen Ltd, now an AstraZeneca company, and Sciona, a company creating personalised gene-based and nutrition analyses.